Related Experiment Video
Updated: May 7, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Management of refractory epilepsy.
1Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.
Topics in Companion Animal Medicine
|September 28, 2013
Summary
Refractory epilepsy in pets is common, affecting about one-third of dogs. New medications and non-drug therapies like electrical stimulation and diet are being explored to improve seizure control when conventional treatments fail.
Area of Science:
- Veterinary Neurology
- Pharmacology
- Epileptology
Background:
- Refractory epilepsy, characterized by poor seizure control or adverse effects from conventional antiepileptic drugs, affects roughly one-third of dogs with epilepsy.
- This condition presents a significant challenge in small animal veterinary practice, necessitating the exploration of alternative treatment strategies.
Purpose of the Study:
- To review current pharmacologic and non-pharmacologic treatment options for refractory epilepsy in dogs and cats.
- To assess the available data on the safety and efficacy of novel therapies for refractory epilepsy in veterinary patients.
Main Methods:
- Literature review of pharmacologic treatments, including newer antiepileptic drugs (e.g., gabapentin, zonisamide, levetiracetam, pregabalin).
- Exploration of non-pharmacologic interventions such as electrical brain stimulation and dietary modifications, drawing parallels with human epilepsy treatments.
- Summary of existing clinical data on the safety and efficacy of these varied treatment modalities.
Main Results:
- Several newer antiepileptic drugs approved for human use have been investigated in veterinary patients with refractory epilepsy.
- Non-pharmacologic approaches, including electrical stimulation and dietary changes, have also shown promise and been evaluated in dogs.
- Current knowledge regarding the safety and efficacy of many treatments for refractory epilepsy in animals is limited.
Conclusions:
- Effective treatment options for refractory epilepsy in dogs and cats remain a critical area of interest.
- Further research, particularly randomized controlled trials, is essential to validate the safety and efficacy of novel pharmacologic and non-pharmacologic therapies.
- Improved treatment strategies are needed to enhance seizure control and quality of life for animals suffering from refractory epilepsy.
More Related Videos
05:54Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
Published on: June 13, 2016
11:29Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
Published on: August 15, 2025
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...